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Abstract
Introduction: An estimated 60%–90% of people with schizophrenia smoke, compared with 15%–
24% of the general population, exacerbating the already high morbidity and mortality rates ob-
served in this population. 
Aims and Methods: This study aimed to assess the feasibility of using a new-generation high strength 
nicotine e-cigarette to modify smoking behavior in individuals with schizophrenia spectrum disorders 
who smoke cigarettes. A single-arm pilot study was conducted with 40 adults with schizophrenia spec-
trum disorders who smoked and did not intend to reduce or quit smoking. Participants were given a 
12-week supply of a JUUL e-cigarette loaded with a 5% nicotine pod. The primary outcome was smoking 
cessation at week 12. Additional outcomes included: smoking reduction, continuous abstinence at week 
24, adoption rate, adherence to the e-cigarette, feasibility, acceptability, and subjective effects.
Results: Sixteen (40%) participants quit by the end of 12 weeks. For the whole sample, we ob-
served an overall, sustained 50% reduction in smoking or smoking abstinence in 37/40 (92.5%) of 
participants and an overall 75% reduction in median cigarettes per day from 25 to six was observed 
by the end of the 12 weeks (p < .001).
Conclusions: A high strength nicotine e-cigarette has the potential to help people with schizophrenia 
spectrum disorders to quit or reduce smoking. Further research with a larger sample and a com-
parator group is needed. The results provide useful information and direction to augment the ex-
isting body of knowledge on smoking cessation for people with schizophrenia spectrum disorders.
Implications: Considering that most people with schizophrenia spectrum disorders continue 
smoking, alternative and efficient interventions to reduce or prevent morbidity and mortality are 
urgently needed. This study showed that adults who smoke and were not motivated to quit, when 
provided a new-generation e-cigarette with high nicotine content, demonstrated substantially 
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decreased cigarette consumption without causing significant side effects. Although not specific-
ally measured in this study, nicotine absorption in new-generation devices has been shown to be 
consistently superior compared with the first generation of e-cigarette devices, and this may help 
explain the lower quit rates in studies using earlier generation devices.
Introduction
An estimated 60%–90% of people with schizophrenia smoke, com-
pared with 15%–24% of the adult general population1–7; this group 
smokes more heavily and is more dependent on tobacco than those 
without mental illness.8 Individuals with schizophrenia extract more 
nicotine from cigarettes compared with those without mental illness 
and have higher blood levels of nicotine after smoking.9 Nicotine’s 
addiction liability is confirmed by the high smoking rates and low 
quit success rates observed despite its well-known adverse impact 
on health.10
Williams et al.11 measured serum nicotine levels and ad libitum 
smoking for 24 + 2 hours using a smoking topography device in 75 
people with schizophrenia who smoked cigarettes compared with 
86 people without mental illness who smoked. People with schizo-
phrenia smoked more cigarettes, took more frequent puffs, took less 
time to smoke a single cigarette, and had a higher nicotine intake 
than those without mental illness who smoked.
As a result of high smoking rates, people with a mental health 
condition also have high rates of morbidity and mortality compared 
with the general population.12,13 Therefore, quitting smoking is par-
ticularly important for this group.
In a meta-analysis of two randomized controlled trials (RCTs) 
that examined the effect of e-cigarettes for smoking cessation in 
general population samples,14,15 participants using an e-cigarette were 
more likely to have abstained from smoking for at least 6 months 
compared with those using a placebo e-cigarette.16 Other systematic 
reviews and meta analyses of the effect of e-cigarette on smoking 
cessation have reported that e-cigarettes have a negative effect on 
cessation17 or were inconclusive.18,19 The discrepancies in findings 
across several systematic reviews may relate to variability in types 
of studies, participants, outcomes, and length of follow-up included 
in each meta-analysis.20 A more recent RCT found that e-cigarettes 
were almost twice as effective for smoking cessation than nicotine-
replacement therapy.21
The number of studies examining e-cigarettes for smoking 
cessation in the general population is now fairly substantial but 
yields mixed conclusions. While far fewer studies have been con-
ducted with people with schizophrenia, emerging research suggests 
that e-cigarettes may be useful for smoking reduction in people 
with schizophrenia spectrum disorders. In the first published study 
of e-cigarettes as a potential cessation or reduction aid for adults 
with schizophrenia who smoked cigarettes, 14 patients not motiv-
ated to stop smoking were provided with a rechargeable e-cigarette 
kit and a 12-week supply of nicotine cartridges and advised to use 
the product ad libitum.20 The e-cigarette was a first-generation 
“Categoria” e-cigarette with replaceable 7.4 mg/mL nicotine cart-
ridges. At 12-month follow-up, 50% of people with schizophrenia 
who smoked cigarettes had reduced their cigarettes per day (CPD) 
by 50%, and a further 14% had quit smoking completely with no 
increase in psychiatric symptoms.22
Subsequently, Pratt et  al.23 enrolled 21 outpatients with severe 
mental illness (schizophrenia, schizoaffective, or bipolar disorder) 
not motivated to quit who smoked at least 10 CPD. Participants 
were given a 4-week supply of a second-generation e-cigarette based 
on each participant’s level of use of cigarettes, and they were evalu-
ated weekly for 1 month. Nineteen participants completed the study. 
The study found a significant reduction in smoking with a mean 
self-reported decline in use of cigarettes from 192 to 67 cigarettes 
per week confirmed by carbon monoxide expired air (CO) reduction 
from 27 to 15 ppm.
In a more recent study, Hickling et  al.24 conducted a 24-week 
pilot study to investigate the efficacy and acceptability of a 6-week 
supply of a first-generation e-cigarette to reduce smoking in 50 
people with severe mental illness who smoked cigarettes and were 
not motivated to quit, including 42 (84%) participants with schizo-
phrenia spectrum disorders. These participants were provided with 
NJOY disposable e-cigarettes with 45 mg/mL nicotine and were en-
couraged to replace cigarettes with e-cigarettes as much as possible. 
At the end of the 6-week supply phase, 37% of participants had 
reduced their tobacco consumption and 7% had stopped smoking. 
Four weeks after the end of the 6-week supply, 26% of participants 
had reduced their tobacco consumption and 5% had quit combust-
ible cigarettes. At final follow-up (24 weeks), 25% of participants 
had reduced their tobacco consumption and 2% had quit smoking 
cigarettes.
The efficiency of nicotine delivery among e-cigarettes has im-
proved substantially since first marketed more than 10 years ago and 
there is a growing consensus that these products are significantly less 
harmful than combustible cigarettes.20,25–27 Recent research indicates 
that nicotine pharmacokinetics of the JUUL e-cigarette with 5% 
nicotine strength (a device that utilizes a nicotine salt formulation) 
approximates the nicotine delivery of combustible cigarettes.28–30 
The 5% nicotine strength product is far more efficient in delivering 
nicotine compared with the pod with 1.5% nicotine strength.31
The aim of this study was to evaluate the feasibility of modifying 
smoking behavior in people with schizophrenia spectrum disorders 
who were not interested in giving up smoking, by providing them 
with a JUUL e-cigarette starter kit and replaceable pods with 5% 
nicotine strength for 12 weeks. We also assessed changes in mental 
health symptoms, body weight, subjective effects of the use of the 
e-cigarettes, and recruitment and retention rates. We considered 
using other e-cigarette devices and nicotine strengths but chose 
the JUUL for its specific characteristics to efficiently deliver high 
strength nicotine. Given the very limited published literature on the 
use of e-cigarettes for smoking reduction or cessation in people with 
schizophrenia, we conducted a single-arm pilot study to inform the 
parameters for a future RCT.
Methods
Design
This was a single-arm, open-label pilot study to observe combustible 
cigarette use behavior in adults with a schizophrenia spectrum dis-
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who were invited to use an e-cigarette. The e-cigarettes were offered 
to participants as an alternative to cigarettes. The design was in-
formed by a conceptual framework for defining feasibility and pilot 
studies developed by Eldridge et al. They argue that pilot studies are 
a subset of feasibility, rather than the two being mutually exclusive,32 
and that single-arm pilot studies (as in the current research) can still 
answer feasibility questions. Therefore, this single-arm pilot study 
aimed to determine if and how the proposed intervention could be 
delivered in practice and how to proceed with testing the interven-
tion in a future, larger study.
Participants
Forty participants were recruited between September and October 
2017. We wrote to physicians, psychiatrists, and other health care 
providers to inform them about the study. Flyers were posted within 
and outside of the Smoking Cessation Center of Catania University 
(Centro per la Prevenzione e Cura del Tabagismo—CPCT), at the 
Policlinico Vittorio Emanuele. Participants were recruited from 
Catania outpatient psychiatric clinics by researchers of CPCT. 
Clinicians from outpatient psychiatric clinics identified suitable par-
ticipants and drew their attention to the study flyers.
As this was a single-arm pilot study, a formal sample size calcula-
tion was not required. However, with approximately 40 participants 
in the study, a 95% confidence interval for the proportion of study 
participants with self-reported complete cessation from combustible 
tobacco cigarettes at each follow-up visit could be constructed to be 
within ±17.6% of the true proportion of people who successfully 
quit. This calculation, performed during the protocol study design, 
was based on a previous study about the impact of e-cigarettes on 
smoking reduction and cessation in adults with schizophrenia who 
smoked,22 which assumed that approximately 20% of participants 
would have achieved complete cessation from tobacco cigarette 
smoking during the entire study period. Up to 40 participants were 
recruited at baseline (BL), as this study assumed a conservative at-
trition rate of 50%. Primary and secondary outcome measures were 
analyzed by including all enrolled participants assuming, on the 
basis of the intention-to-treat principle, that all individuals lost to 
follow-up would be classified as continuing to smoke.33
Inclusion criteria were:
 1. Adults attending psychiatric outpatient clinics in Catania who 
smoked 20 or more cigarettes daily were included. The rationales 
for these criteria were the opportunities, to study a potentially 
effective harm reduction alternative for heavy smokers who were 
cigarette dependent and who had difficulties to quit and to com-
pare the results to those of a previous study that enrolled heavy 
smokers with schizophrenia spectrum disorders who smoked 20 
or more combustible cigarettes.22
 2. Aged 21–65 years.
 3. Not intending to reduce or quit smoking.
 4. Able to meet the criteria for a schizophrenia spectrum disorder 
diagnosis without evidence of current exacerbation of illness, 
defined as “no relapse to hospitalization within the last three 
months and no change in antipsychotic medication within the 
last month.” 34 In terms of this last inclusion criterion, a clinical 
psychologist or a psychiatrist not involved in the study made the 
diagnosis based on criteria from the DSM-V.35
Exclusion criteria were: (1) pregnancy, (2) breastfeeding, (3) myo-
cardial infarction or angina pectoris within the past 3 months, (4) 
current poorly controlled asthma or chronic obstructive pulmonary 
disease, (5) use of smokeless tobacco or any other tobacco products, 
and (6) use of nicotine-replacement therapy or other smoking cessa-
tion therapies within the last 3 months.
Intervention
At the BL visit, participants were given a free e-cigarette starter kit 
containing one JUUL device with a charger and 5% nicotine pods, 
Virginia tobacco flavor with instructions on how to charge, activate, 
and use the e-cigarette. A 4-week supply of pods equivalent to their 
current cigarette smoking behavior, according to the manufacturer’s 
guidelines, was supplied to each participant (one pod for every 
packet of 20 cigarettes; mean 128, minimum 80, and maximum 
200). Eligible participants were invited to use a JUUL e-cigarette for 
at least 12 weeks and were followed up prospectively for 24 weeks. 
Participants received a 4-week supply of pods on three occasions, 
BL, week 4 (study visit 2), and week 8 (study visit 3). Participants 
were informed verbally and in writing through the patient informa-
tion sheet and consent form, that the product was potentially less 
harmful than combustible cigarettes and could be used as a cigar-
ette substitute as much as they liked. Researchers could be contacted 
by phone if participants needed technical and medical assistance. 
Limited behavioral support was provided as part of the intervention 
and included behavior substitution of combustible cigarettes with 
e-cigarettes and self-monitoring of combustible cigarette consump-
tion through the use of study diaries.36
Participants attended a total of five study visits at the smoking 
cessation clinic, University of Catania (Figure 1).
The device used in the study—JUUL is an e-cigarette that was cre-
ated by PAX Labs and is a closed pod e-cigarette product. The pod 
contains 0.7 mL of e-liquid and up to 5% nicotine by weight. The 
e-liquid composition includes propylene glycol, glycerol, nicotine, 
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benzoic acid, and flavoring. JUUL is breath actuated, has no user 
modifiable settings, and is a temperature-regulated e-cigarette resem-
bling a USB flash drive. The battery (200 mAh) is not removable and 
incorporates battery regulation features. The pod contains nicotine 
salts that are absorbed more readily into the bloodstream, are toler-
ated by the airway epithelium, and are able to deliver high concen-
trations of nicotine at a rate similar to cigarettes.28,29,37
The e-cigarettes used in the study were donated by the manu-
facturer, PAX Labs (on June 13, 2017 the company became known 
as JUUL Labs). At the time the research was conducted JUUL Labs 
were not part owned by Altria, a tobacco company. Due to the lack 
of availability at that time in Italy, PAX Labs (at that point renamed 
JUUL Labs) also agreed to supply cartridges/pods for a further 
3 months after the end of the pilot to participants who expressed 
a wish to continue using them. No separate funding was secured 
for the study. Altria Group (formerly Philip Morris Companies) ac-
quired a 35% stake in JUUL Labs on December 20, 2018 but the 
study was completed before Altria invested in JUUL.
Ethical approval was obtained for both the Italian University of 
Catania and the University of Stirling ethics committee.
Measures
The following information was recorded at BL: demographics, 
smoking history and pack-years, CO, vital signs and body weight, 
and mental health symptoms. At study visits 2 (week 4), 3 (week 8), 
participants were invited back for further assessments CO, vital signs 
and body weight, mental health symptoms, and subjective effects 
and to return unused study products, check their study diary, and re-
ceive another 4-week supply of pods. At study visit 4 (week 12), par-
ticipants returned unused study products and their study diary was 
checked. At this visit the following data were recorded: number of 
cigarettes smoked, pods used daily since the last visit, CO, vital signs 
and body weight, mental health symptoms, and subjective effects. 
At study visit 5 (week 24), participants’ study diaries were checked. 
At this visit the following data were recorded: number of cigarettes 
smoked daily since the last visit, CO, vital signs, body weight, and 
mental health symptoms.
Cigarette dependence was measured by the Fagerstrom test for 
cigarette dependence.38 The self-report questionnaire consists of 
six questions. The scores obtained on the test permit the classifi-
cation of cigarette dependence into three levels: mild (0–3 points), 
moderate (4–6 points), and severe (7–10 points). CO was measured 
by a portable device (Micro CO, Micro Medical Ltd, Kent, United 
Kingdom).
Smoking abstinence was measured by continuous abstinence 
rates (CARs), defined as the percentage of participants remaining 
continuously abstinent from week 9 to each in-clinic visit through 
week 24. CARs during weeks 9–12 were the primary endpoint and 
CARs during weeks 9–24 were one of the secondary endpoints. 
CARs were verified by self-report and study diaries and exhaled 
carbon monoxide (≤10 ppm) measurements.
In between study visits participants were asked to maintain a 
daily study diary recording product use, number of tobacco cigar-
ettes smoked, and adverse events (AEs). Participants reported AEs 
from a defined list of side effects and were also asked to keep track of 
any AEs they felt may be associated with e-cigarette using the study 
diary. The diary was reviewed with the participant by the researcher 
at each study visit. Participants who did not complete their diary be-
tween study visits completed it during the study visit.
Mental health symptoms were measured with the Scale for the 
Assessment of Positive Symptoms (SAPS)39 and the Scale for the 
Assessment of Negative Symptoms (SANS),40 two of the most widely 
used scales to measure symptoms of schizophrenia.41 The SANS and 
SAPS are both used frequently in clinical and research settings and 
reliability and validity have been shown to be consistent in multiple 
cross-cultural settings.42 SAPS measures positive symptoms on a 34 
item, 6-point scale; four domains (hallucinations, delusions, bizarre 
behavior, and positive formal thought disorder) are rated from 0 (ab-
sent) to 5 (severe). SANS measures negative symptoms on a 25 item, 
6-point scale. Items are listed under the five domains of affective 
blunting, alogia, avolition/apathy, anhedonia/asociality, and atten-
tion and rated from 0 (absent) to 5 (severe).
Subjective effects were assessed by Modified Cigarette Evaluation 
Questionnaire (mCEQ) scoring that reported frequency and percent 
of participants reporting (1) enjoyment of respiratory tract sensa-
tions, (2) psychological reward, and (3) satisfaction, among users 
of e-cigarettes. The mCEQ has good reliability and validity43 and 
was used to examine subjective effects of e-cigarette use on respira-
tory tract sensations, acceptability of e-cigarettes as substitutes for 
combustible tobacco cigarettes, psychological reward, satisfaction, 
craving reduction, aversion, and enjoyment.
Previous studies have used this questionnaire for e-cigarettes.44–46 
It is a self-administered questionnaire that contains 12 items 
covering both the reinforcing and the aversive effects of smoking. 
Participants were asked to rate the extent to which the e-cigarette 
they used was satisfying, tasted good, made them dizzy, calmed them 
down, helped them concentrate, made them feel more awake, re-
duced appetite, made them nauseated, decreased irritability, pro-
duced enjoyable sensations in the throat and chest, immediately 
reduced craving for cigarettes and was enjoyable to smoke. The 
items were rated on a 7-point scale of 1 (not at all), 2 (very little), 3 
(a little), 4 (moderately), 5 (a lot), 6 (quite a lot), and 7 (extremely). 
The mCEQ uses three multi-item domains (subscales) and two single 
items: “Smoking Satisfaction” (items 1, 2, plus item 12, the range of 
scores is minimum 3, maximum 21); “Psychological Reward” (items 
4–8, the range of scores is minimum 5, maximum 35); “Aversion” 
(items 9 and 10, the range of scores is minimum 2, maximum 14); 
“Enjoyment of Respiratory Tract Sensations” (item 3, the range of 
scores is minimum 1, maximum 7); and “Craving Reduction” (item 
11, the range of scores is minimum 1, maximum 7). Higher scores 
indicate greater intensity of each smoking effect with, for example, 
greater satisfaction or psychological reward after vaping.
Outcomes
The primary outcome was 12-week CARs (abstinence from combust-
ible cigarettes) during the last 4 weeks (weeks 9–12) of the treatment 
period of 3 months, defined according to CARs 9–12.46 Rates were veri-
fied not only by self-reported declarations and study diaries but also 
by means of exhaled carbon monoxide (≤10 ppm) measurements.2,47 
Participants who met these criteria were referred to as people who quit.
Secondary outcomes were:
 1. Continuous smoking reduction was defined as a reduction by 
≥50% in the number of CPD from weeks 9 to 12 compared with 
BL. CO levels were measured to verify smoking status and con-
firm also a possible reduction compared with BL. These partici-
pants were referred to as people who reduced. No change was 
defined as participants with a self-reported no change in tobacco 
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the final week 12 follow-up visit were categorized as people who 
continued to smoke.
 2. CARs at week 24 (CARs 9–24) were defined as sustained self-
reported abstinence from tobacco smoking for weeks 9–24 with 
CO levels of ≤10 ppm.2,47
 3. Continuous ≥50% reduction in the number of CPD at week 
24 was defined as sustained self-reported ≥50% reduction in 
the number of CPD compared with BL from weeks 9 to 24 
follow-up visit. CO levels were measured by the Micro CO to 
verify smoking status and confirm a reduction, in terms of low 
number, compared with BL.48
 4. Feasibility and acceptability as measured by participants’ vital 
signs, weight, psychopathological changes, and reported AEs 
from a defined list of side effects. They were also asked to keep 
track of any AEs they felt may be associated with e-cigarette 
using the study diary. Subjective effects of using the e-cigarette 
were assessed by scoring of mCEQ; adoption rate and adherence 
to e-cigarette use were also assessed. Differences between BL 
(visit 1) and week 12 (visit 4) for vital signs (blood pressure [BP], 
heart rate [HR]) and weight were measured. Changes in positive 
and negative symptoms of schizophrenia were measured by the 
SANS and SAPS between BL (visit 1) and week 12 (visit 4).
Acceptability of e-cigarettes as substitutes for cigarettes was also 
assessed; the adoption rate and adherence to product use were 
measured by (1) daily use of e-cigarettes during the 12 weeks of ob-
servation, and (2) ≥50% e-cigarette use during the 12 weeks of ob-
servation, which equals at least 42 days of usage. Participants were 
asked to keep track of the amount they used their e-cigarette using 
a study diary. The diary was reviewed with the participant by the 
researcher at each study visit.
For a table of measures and time points, see Table 1.
Data Analysis
Primary and secondary outcome measures were computed by 
including all enrolled participants assuming that, on the basis of the 
intention-to-treat principle, all individuals lost to follow-up would 
be classified as people who continued to smoke.48 Parametric and 
nonparametric data were expressed as mean (±SD) and median, 
interquartile range (IQR) respectively. The proportion of people 
who quit and people who reduced were reported descriptively. The 
change in the number of CPD for each visit compared with BL was 
assessed with the Wilcoxon signed rank test. No adjustments for 
multiple comparisons were performed given the exploratory nature 
of this study.
Feasibility and acceptability measures (vital signs and weight, 
SAPS, SANS, AEs, Serious Adverse Events [SAEs], mCEQ) were re-
ported descriptively. Descriptive statistics were calculated for patient 
demographics. All p values were two-sided with statistical signifi-
cance evaluated at the .05 alpha level and 95% confidence interval. 
Analyses were performed in SPSS Version 23 (Statistical Package for 
Social Sciences Program, IBM Corp., Armonk, NY).
Results
Participant Characteristics
Fifty-six adults with schizophrenia spectrum disorders who smoked 
cigarettes responded to the study advert. A total of 40 participants 
(M 26; F 14; mean [±SD] aged 48.3 [±12.1] years) adults who 
smoked (mean [±SD] pack/years of 45.4 [±23.9]) consented to par-
ticipate and were included in the study (Table 2 and Figure 2). The 
40 participants were recruited over a 2-month period. BL character-
istics of those who were lost to follow-up were not significantly dif-
ferent from participants who completed the study. Recruitment and 
12-week follow-up data are shown in the study flowchart (Figure 2).
Changes in Smoking Behavior
Participants’ tobacco consumption at BL and at 12 weeks is shown 
in Table 3.
Smoking Cessation
At the 12-week study visits 16/40 (40%) people had quit smoking, 
with 16/16 (100%) still using their JUUL e-cigarette (Table 3 and 
Figure 2; Supplementary Figure 1). At the final follow-up visit at 
week 24, 14/40 (35%) people had quit smoking with 14/14 (100%) 
still using their JUUL e-cigarette by week 24.
Smoking Reduction
There was a significant decrease in the number of CPD between BL 
and 12 and 24 weeks follow-up. A ≥50% reduction in the number 
Table 1.  Measures and Related Time Points
Baseline (visit 1) Week 4 (visit 2) Week 8 (visit 3) Week 12 (visit 4) Week 24 (visit 5)
Primary outcomes
 12-Week continuous abstinence for weeks 9–12 x x
Secondary outcomes
 Sustained smoking reduction for weeks 9–12 x x
 24-Week continuous abstinence for weeks 9–24 x x x
 Sustained smoking reduction for weeks 9–24 x x x
 Vital signs (BP and HR) x x x x
 Weight x x x x
 SANS and SAPS x x x x
 Adoption rate and adherence to product use x x x
 AEs x x x x
 mCEQ x x x x
 CO x x x x x
 FTCD x
AEs = adverse events; BP = blood pressure; CO = exhaled carbon monoxide; FTCD = Fagerstrom test for cigarette dependence; HR = heart rate; mCEQ = Modified 
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of CPD compared with BL for the 4 weeks period prior to the week 
12 study visit and was found in 21/40 (52.5%) participants, with a 
median of 25 CPD at BL (IQR 20, 40) decreasing significantly to 10 
CPD (IQR 8.5, 15) (p < .001) (Supplementary Table 1).
A ≥50% reduction in the number of CPD at week 24 was found 
in 23/40 (57.5%) (Supplementary Figure 1) participants with a me-
dian of 25 CPD at BL (IQR 20, 40) decreasing significantly to 11 
CPD (IQR 8.6, 16) (p < .001).
Acceptability
Adoption Rate and Adherence to Product Use
All participants that completed the full schedule of visits (n = 37) re-
ported using the e-cigarette each day over the 12 weeks, with a me-
dian (IQR) amount of e-cigarettes’ pods of one per day over the 
study duration.
Attrition
At week 12, the retention rate was high, with 37 (92.5%) partici-
pants completing all study visits and attending their follow-up visit. 
One participant chose not to participate after week 2 because he 
wanted to continue to smoke. The same 37 participants attended the 
final follow-up visit at week 24. Two participants dropped out of the 
study after week 4 because they did not find the e-cigarette accept-
able and reported that it caused them to cough. Participants’ vital 
signs, weight, and psychopathological changes from BL to week 12 
are shown in Supplementary Table 2.
Vital Signs (BP and HR), Weight, and Mental Health
The data indicated that participants’ mean systolic and diastolic BP 
and HR significantly decreased between BL (visit 1)  and 12-week 
follow-up (visit 4) (p = <.0001) (Supplementary Table 2). Participants 
mean weight between BL (visit 1)  and 12-week follow-up (visit 
4) also significantly decreased (p = .0052) (Supplementary Table 2).
Positive and negative symptoms of schizophrenia were not sig-
nificantly different after using e-cigarettes from BL (visit 1)  to 
week 12 (visit 4), suggesting absence of psychopathological ex-
acerbation during the period when participants were e-cigarettes. 
(Supplementary Table 2).
Adverse Events
Reported AEs among participants were dry cough (7.8%), headache 
(5.4%), and throat irritation (2.7%). These events were rare and typ-
ical withdrawal symptoms of smoking cessation were not reported. 
Moreover, there were no reported SAEs during the study.
Subjective Effects
The majority of participants (61.9%) were satisfied with using the 
e-cigarette and obtained psychological reward (85%) that means 
e-cigarette’ usage calm down, users feel more awake, less irritable, 
helped with concentration, and reduce hunger for food. The ma-
jority of participants (77.5%) reported no aversion to the use of 
the e-cigarette use and moderate to significant enjoyment (76.1%). 
30.1% also reported a moderate craving reduction associated with 
e-cigarette use (Supplementary Table 3).
Discussion
In this single-arm study, we assessed whether participants with 
schizophrenia spectrum disorder could be recruited, examined the 
feasibility of offering an e-cigarette, assessed changes to smoking be-
havior, and evaluated the acceptability of an e-cigarette. Participants 
were recruited within a 2-month period and the majority (92.5%) 
completed the study. At week 12, 16 of the 40 (40%) participants 
enrolled in study stopped smoking completely and continued to use 
the e-cigarette product provided. At week 24, 14 of the 40 (35%) 
participants enrolled in the study completely stopped smoking and 
continued to use the e-cigarette product provided. This proportion 
of people who quit smoking is higher than that found in previous 
studies with similar patient groups. For example, in the first ever 
study of e-cigarettes with patients with schizophrenia spectrum dis-
orders,22 at week 52, two of 14 (14%) people who smoked at least 
20 CPD stopped smoking completely with an e-cigarette. In a study 
in the United States,23 two of 19 (10.5%) participants with serious 
mental illness switched completely to e-cigarettes at the 4-week 
assessment. In a more recent study conducted in United Kingdom 
by Hickling et  al.,24 in 50 people with severe mental illness who 
smoked, by the end of the e-cigarette supply phase at week 6, three 
of 50 participants (7%) reported having stopped smoking tobacco 
cigarettes.
In week 24 (the end) of this study, a further 57.5% of the parti-
cipants (23 of 40) were able to sustain ≥50% cigarette reduction by 
continuing to use the e-cigarette provided. This finding is similar to 
that in previous studies with similar patient groups. For example, 
Table 2. Participants’ Characteristics
n (%)
Sociodemographic characteristics at baseline
 Gender
  Male 26 (65)
  Female 14 (35)
 Age: mean (SD) 48.3 (12.1)
 Age range
  18–24 1 (2.5)
  25–44 13 (32.5)
  45–65 26 (65)
 Education: n (%)
  Middle school 22 (55)
  High school 17 (42.5)
  University 1 (2.5)
 Ethnicity
  White Caucasian 40 (100)
Smoking history
 CPD: mean (SD) 28 (9)
 Age of onset of smoking: mean (SD) 15.4 (1.2)
 Length of time smoking: mean (SD) 33.5 (12.2)
 Pack/years: mean (SD) 45.4 (23.9)
 Smokers who have made previous  
cessation attempts: n (%)
14 (35%)
 Smokers who had previously used an  
e-cigarette, either regularly or tried: n (%)
12 (30%)
 FTCD: mean (SD) 8.3 (1.8)
Mental health history and status
 Age onset of schizophrenia spectrum  
disorders: mean (SD)
21.9 (2.8)
  SAPS at baseline: mean (SD) 42.9 (23.7)
  SANS at baseline: mean (SD) 43.3 (21.7)
CPD = cigarettes per day; FTCD = Fagerstrom test for cigarette dependence; 
SANS = Scale for the Assessment of Negative Symptoms; SAPS = Scale for the 
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in Caponnetto et  al. mentioned above,22 at week 52, seven of 14 
(50%) participants were able to sustain ≥50% cigarette reduction, 
verified by a significant reduction in CO levels by 12 months. Pratt 
et al.23 reported a 65% reduction in cigarette use in their partici-
pants. In the study by Hickling et al.,24 by the end of the e-cigarette 
supply phase 37% of participants had reduced the number of CPD 
by ≥50%.
These preliminary findings are promising in view of the fact 
that all participants in the study were, by eligibility criteria, not 
motivated to quit smoking. Moreover, although it is not directly 
Figure 2. Study flowchart.
Table 3. Participants’ Traditional Cigarette Consumption at Baseline and at 12 and 24 Weeks
Time point N Obs Variable Mean SD Median
Baseline (visit 1) 40 CPD 27.95 9.14 25.00
CO 34.03 10.95 30.00
Baseline (visit 1) 37 CPD 28.59 9.79 25.00
Participants who completed the study CO 33.23 10.97 30.00
Week 12 (visit 4) 37 CPD 6.38 6.89 6.00
CO 8.19 6.53 10.00
Week 24 (visit 5) 37 CPD 6.91 6.77 7.00
CO 9.29 8.61 10.00
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comparable with standard smoking cessation and/or reduction 
studies because of its design, success rates in the present study are 
not only similar to those obtained with approved pharmaceut-
ical products,49,50 but also greater than those observed for first-
generation and second-generation e-cigarettes with similar patient 
groups.22–24
This study showed that use of a new-generation e-cigarette, with 
a high nicotine content, in participants not motivated to quit, sub-
stantially decreased cigarette consumption without causing signifi-
cant side effects. Although not specifically measured in this study, 
nicotine absorption using new-generation devices has been shown 
to be consistently superior compared with the first e-cigarette gen-
eration devices,51,52 which may form part of the explanation for 
a higher quit rate than in studies using earlier generation devices. 
Other factors potentially contributing to the higher quit rates com-
pared with previous studies might include the ease of use and dur-
ability of the e-cigarette device. This is in marked contrast to one of 
our earlier studies22 in which participants used a five-piece e-cigarette 
product that was complicated to use (Supplementary Figure 2). For 
example, in that study, batteries, chargers, and atomizing devices fre-
quently broke, and cartridges often leaked liquid into the mouth and 
needed frequent changing. Therefore, avoiding unnecessary stress to 
the participants may also have influenced acceptability and adher-
ence. Participants’ responses to the mCEQ suggest they found the 
JUUL satisfying and enjoyable, and this likely enhanced adherence. 
Given its technological advantages, as well as its pharmacokinetic 
profile similar to that of combustible tobacco cigarettes,28,29,53,54 the 
e-cigarette used in this study may have provided a more “cigarette-
like” experience which may have potentially stimulated switching, 
although this was not formally assessed.
The study procedures appeared acceptable to participants. This is 
evidenced by the high retention rate. Given that few problems were 
experienced in conducting the research, the study procedures were 
also feasible. There is also evidence of acceptability in terms of the 
short-term markers of physical and mental health assessed during 
the study. Participants showed significant improvements in BP and 
HR, did not gain weight, and exhibited no exacerbation in psycho-
pathology. Other studies suggest that symptoms of schizophrenia are 
not increased in patients who reduce their smoking using nicotine 
patches55,56,57 or early generation e-cigarettes.22 However, a minority 
of study participants reported the administration of SAPS and SANS 
at each visit was too long, and so this needs to be taken into consid-
eration for future studies.
There were several limitations in this study. First, this was an 
uncontrolled study and the lack of a control group and blinding 
limits the internal validity and external validity of the findings. 
Confounding is a major threat to the validity of uncontrolled data. 
Thus, this underscores the need for a future RCT. Nonrandomized 
or single-arm pilot studies are an acceptable approach to testing the 
feasibility of interventions.32 These types of studies constitute re-
search in which all or part of an intervention is evaluated and other 
study procedures are piloted for a future definitive trial, but without 
randomization of participants. These studies are used to determine 
whether an intervention is appropriate for further testing. Performing 
this kind of study may be indicated when there are few previously 
published studies or existing data using a specific intervention tech-
nique. Commonly a number of issues are examined in these studies: 
initial efficacy, acceptability, demand, implementation, practicality, 
and adaption.32,55,56 Given the very limited existing literature on the 
use of e-cigarettes for smoking reduction or cessation in adults with 
schizophrenia and no literature on use of a high strength nicotine 
e-cigarettes, it was decided that a single-arm pilot study should be 
the first step to gather data to inform the design of a future trial.
Characteristics of the sample and the e-cigarette used limit 
the generalizability of the findings. We enrolled participants who 
smoked at least 20 CPD and who were unwilling to quit, and there-
fore our findings cannot be assumed to apply to all adults with 
schizophrenia who smoke cigarettes. Specifically, direct comparison 
with other smoking cessation studies involving individuals who 
smoke—and who are motivated to quit—cannot be made. All par-
ticipants were from urban Sicilian outpatients settings and may not 
be valid for other population samples. Lastly, because only a single 
nicotine strength (ie, 5%) and a single flavor (ie, Virginia tobacco) 
were investigated in this study, it is possible that the study did not 
provide options that could have increased acceptability and cessa-
tion success rates. Other research has suggested that unrestricted ac-
cess to a wider selection of e-liquid nicotine strengths and flavors 
can play an important role in the attractiveness and success rates of 
these products.58
In conclusion, preliminary positive results from this single-arm 
pilot study suggest that this intervention could be tested in an RCT. It 
will be important to discard or modify those parts of the assessment 
procedures that participants reported were burdensome, such as the 
duration of time required for administration of SAPS and SANS at 
each visit. Many participants also wanted to use the e-cigarette for 
a longer period of time. In addition to this, participants requested 
more counseling about how to give up smoking and vaping; hence, 
a specific brief smoking cessation counseling intervention could be 
added to help individuals who smoke to switch first to an e-cigarette 
and then progressively become totally smoke and vape free. A future 
RCT could also include study sites in other countries to improve 
generalizability.
In summary, this study aimed to conduct preliminary research to 
begin to determine the efficacy of a high strength nicotine e-cigarette 
in a group of people with schizophrenia spectrum disorders who 
smoked cigarettes. The results provide useful information and direc-
tion to add to the existing body of knowledge on smoking cessation 
for this group.
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